Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tadekinig alfa (IL-18BP) / AB2 Bio
2018-003199-10: OPEN-LABEL STUDY: THERAPEUTIC USE OF TADEKINIG ALFA IN NLRC4 MUTATION AND XIAP DEFICIENCY	Not yet recruiting	3	10	Europe	Tadekinig alfa, r-hIL-18BP, Solution for injection	AB2 Bio Ltd., AB2 Bio Ltd.	NLRC4 mutationXIAP deficiency, NLRC4 mutationXIAP deficiency, Diseases [C] - Immune System Diseases [C20]
NCT03113760 / 2018-003297-27: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency	Completed	3	15	Europe, Canada, US	Tadekinig alfa, IL-18BP, r-hIL-18BP, 0.9% sodium chloride	AB2 Bio Ltd.	NLRC4-MAS, XIAP Deficiency	10/23	11/23
NCT03512314 / 2018-003199-10: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension	Active, not recruiting	3	10	Europe, Canada, US	Tadekinig alfa, r-hIL-18BP	AB2 Bio Ltd., AB2 Bio Ltd.	XIAP Deficiency, NLRC4-MAS	09/24	10/24
NCT05306080: Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome	Recruiting	1	10	US	Tadekinig alfa (IL-18BP)	University of Pennsylvania	CRS - Cytokine Release Syndrome, HLH	01/25	04/25